Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ORGO 
Organogenesis Holdings Inc (ORGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/23/2025: ORGO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.6% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 729.74M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 4 | Beta 1.48 | 52 Weeks Range 2.61 - 7.08 | Updated Date 12/23/2025 |
52 Weeks Range 2.61 - 7.08 | Updated Date 12/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.22% | Operating Margin (TTM) 14.69% |
Management Effectiveness
Return on Assets (TTM) 0.18% | Return on Equity (TTM) 0.3% |
Valuation
Trailing PE - | Forward PE 12.32 | Enterprise Value 832584330 | Price to Sales(TTM) 1.57 |
Enterprise Value 832584330 | Price to Sales(TTM) 1.57 | ||
Enterprise Value to Revenue 1.79 | Enterprise Value to EBITDA 198.16 | Shares Outstanding 126912142 | Shares Floating 55899722 |
Shares Outstanding 126912142 | Shares Floating 55899722 | ||
Percent Insiders 46.69 | Percent Institutions 54.5 |
Upturn AI SWOT
Organogenesis Holdings Inc
Company Overview
History and Background
Organogenesis Holdings Inc. was founded in 1987 and is a pioneer in regenerative medicine. It has focused on developing and commercializing advanced wound care and surgical products. Key milestones include the development of its proprietary amniotic tissue platform and significant FDA approvals for its regenerative wound care solutions.
Core Business Areas
- Advanced Wound Care: Focuses on developing and commercializing regenerative wound care products that leverage the body's natural healing processes to treat chronic and complex wounds. This includes products for diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
- Surgical Specialties: Offers regenerative tissue products for use in surgical procedures to aid in tissue repair and regeneration, particularly in areas like spinal fusion, orthopedics, and general surgery.
Leadership and Structure
Organogenesis Holdings Inc. is led by a management team with expertise in the biotechnology and medical device industries. The company operates through its subsidiaries, Organogenesis Inc., which handles product development and commercialization.
Top Products and Market Share
Key Offerings
- PuraDerm: A proprietary amniotic membrane allograft used in advanced wound care for its ability to promote healing and reduce inflammation. Competitors include MiMedx Group (EpiFix), Smith & Nephew (CICA-WoundCare), and other regenerative medicine companies.
- Apligraf: A bioengineered skin substitute used for the treatment of venous leg ulcers and diabetic foot ulcers, providing a scaffold for cell growth and tissue regeneration. Competitors include Shire (Dermagraft), Organ Therapeutics (NuFace), and others in the cellular and tissue-based products market.
- ChronoDerm: Another regenerative wound care product designed to accelerate healing and reduce scarring. Competitors are similar to those for Apligraf and PuraDerm.
Market Dynamics
Industry Overview
The regenerative medicine and advanced wound care market is characterized by rapid innovation, increasing prevalence of chronic diseases (like diabetes and cardiovascular conditions) leading to complex wounds, and a growing demand for less invasive and more effective treatment options. Regulatory approvals play a crucial role in market access and growth.
Positioning
Organogenesis Holdings Inc. is positioned as a leader in regenerative medicine, particularly in the advanced wound care segment, with a strong focus on amniotic and cellular-based therapies. Its competitive advantages include a proprietary technology platform, a portfolio of FDA-approved products, and established physician relationships.
Total Addressable Market (TAM)
The global advanced wound care market is projected to reach tens of billions of dollars in the coming years. Organogenesis Holdings Inc. is positioned to capture a significant portion of this market by addressing unmet needs in chronic wound management and surgical regeneration, although its current market share is a fraction of the total TAM.
Upturn SWOT Analysis
Strengths
- Proprietary regenerative medicine technology platform.
- Portfolio of FDA-approved products for advanced wound care and surgical applications.
- Experienced management team with deep industry knowledge.
- Established relationships with healthcare providers and distributors.
- Strong focus on research and development for pipeline expansion.
Weaknesses
- Dependence on a limited number of core products.
- Potential for intense competition and pricing pressures.
- Reliance on third-party payers for reimbursement.
- Challenges in scaling manufacturing to meet growing demand.
Opportunities
- Expanding product indications and seeking new regulatory approvals.
- Geographic expansion into international markets.
- Strategic partnerships and collaborations to enhance market reach.
- Acquisition of complementary technologies or companies.
- Growing awareness and adoption of regenerative medicine solutions.
Threats
- Changes in healthcare reimbursement policies.
- Increased competition from established and emerging players.
- Adverse clinical trial outcomes or regulatory setbacks.
- Economic downturns impacting healthcare spending.
- Development of alternative, less expensive treatment modalities.
Competitors and Market Share
Key Competitors
- MiMedx Group (MDXG)
- Smith & Nephew (SNN)
- Johnson & Johnson (JNJ)
Competitive Landscape
Organogenesis Holdings Inc. faces competition from larger, more diversified healthcare companies like Johnson & Johnson and specialized regenerative medicine firms like MiMedx. Its advantages lie in its focused expertise and proprietary amniotic and cellular technology, while disadvantages can include resource limitations compared to giants and the need to constantly innovate to stay ahead.
Growth Trajectory and Initiatives
Historical Growth: Organogenesis Holdings Inc. has demonstrated a strong historical revenue growth trajectory, driven by the increasing adoption of its regenerative medicine products in the wound care and surgical markets. This growth is indicative of successful commercialization efforts and market penetration.
Future Projections: Analyst projections for Organogenesis Holdings Inc. generally anticipate continued revenue growth, driven by expanding product applications, market penetration, and potential new product launches. However, profitability timelines may vary, with some projections suggesting a path to profitability in the coming years.
Recent Initiatives: Recent initiatives have likely included expanding sales force, focusing on key therapeutic areas, and investing in R&D to broaden its product pipeline and explore new applications for its regenerative medicine platform.
Summary
Organogenesis Holdings Inc. is a promising player in the regenerative medicine sector with strong revenue growth and a robust technological foundation. Its specialized products for advanced wound care and surgical applications are gaining traction. However, the company needs to address its persistent net losses and navigate a competitive landscape. Continued investment in R&D and strategic market expansion are crucial for its long-term success and path to profitability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Financial data aggregators (e.g., Yahoo Finance, Bloomberg)
- Industry reports and market analysis publications
Disclaimers:
This JSON output is based on publicly available information and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial professional and conducting independent research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Organogenesis Holdings Inc
Exchange NASDAQ | Headquaters Canton, MA, United States | ||
IPO Launch date 2017-01-05 | President, CEO, Chair of the Board Mr. Gary S. Gillheeney Sr. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 869 | Website https://organogenesis.com |
Full time employees 869 | Website https://organogenesis.com | ||
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.